Shawna Weisler, MD
Endocrinology · Burbank, CANPI 1962501858
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.9%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 41 manufacturers reported payments, led by AstraZeneca at 53.1% of the total. Reporting peaked in 2019 at $16,806 and has fallen 89.5% since, to $1,768 in 2025. Among endocrinology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 695 payments — averaging $64.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$24K
- Dexcom, Inc.$9K
- Novo Nordisk$3K
- Mannkind Corporation$1K
- Lilly USA, LLC$838
- Abbott$809
- plus $6K from 35 others
What the payments were for
- Consulting fees$1,8364%
- Speaking & faculty fees$26,51259%
- Travel & lodging$1,1583%
- Food & beverage$15,20534%
- Education$1600%
- Gifts$1190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 75 | $23,890 |
| Dexcom, Inc. | 59 | $8,813 |
| Novo Nordisk | 150 | $3,135 |
| Mannkind Corporation | 55 | $1,381 |
| Lilly USA, LLC | 44 | $838 |
| Abbott | 38 | $809 |
| Xeris Pharmaceuticals, Inc. | 31 | $730 |
| Sanofi-aventis U.S. LLC | 35 | $727 |
| AbbVie | 22 | $567 |
| Sequel Med Tech, LLC | 15 | $459 |
| Boehringer Ingelheim | 18 | $423 |
| Amgen | 14 | $359 |
| Companion Medical, Inc. | 11 | $326 |
| Antares Pharma, Inc. | 11 | $241 |
| IBSA Pharma Inc. | 20 | $237 |
| Merck | 11 | $204 |
| Radius Health, Inc. | 6 | $157 |
| Zealand Pharma US, Inc. | 10 | $140 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $138 |
| Tandem Diabetes Care, Inc. | 9 | $134 |
| Amarin Pharma, Inc. | 5 | $131 |
| Valeritas, Inc. | 11 | $131 |
| Bayer | 1 | $130 |
| Medtronic(2 entities) | 5 | $97 |
| Eisai Inc. | 4 | $84 |
| Insulet Corporation | 4 | $79 |
| Currax Pharmaceuticals LLC | 4 | $66 |
| Corcept Therapeutics | 3 | $64 |
| Halozyme Inc | 3 | $60 |
| Kowa Pharmaceuticals America, Inc. | 3 | $55 |
| Alfasigma USA, Inc. | 3 | $54 |
| Vistapharm, Inc. | 3 | $51 |
| Shire North American Group Inc | 2 | $48 |
| Biogen | 1 | $42 |
| BD | 2 | $40 |
| Embecta Corp. | 1 | $30 |
| Kyowa Kirin, Inc. | 1 | $29 |
| Cequr Corporation | 1 | $26 |
| Vivus LLC | 1 | $25 |
| Amryt Pharma Holdings Ltd | 1 | $21 |
| Ascensia Diabetes Care US Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$19,385
- DEXCOM G6 CGM SYSTEM$4,211
- BYDUREON$3,400
- DEXCOM G6 TRANSMITTER$2,448
- DEXCOM CGM$1,283
- RYBELSUS$375
- AFREZZA$360
- Ozempic$359
- TWIIST$172
- FREESTYLE LIBRE 3$155
- NEFFY$138
- Kerendia$130
- Synthroid$125
- RECORLEV$121
How this compares
$44,990 in reported general payments places this provider in the 90th percentile of 58 endocrinology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 335 | $415,479 |
| JardianceEmpagliflozin | 195 | $198,826 |
| TrulicityDulaglutide | 133 | $180,207 |
| MounjaroTirzepatide | 117 | $151,039 |
| FarxigaDapagliflozin Propanediol | 125 | $118,980 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 73 | $89,046 |
| RybelsusSemaglutide | 49 | $72,914 |
| Tresiba Flextouch U-100Insulin Degludec | 103 | $65,100 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 66 | $54,409 |
| JanuviaSitagliptin Phosphate | 40 | $47,957 |
| TradjentaLinagliptin | 46 | $42,537 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 29 | $30,826 |
| Tresiba Flextouch U-200Insulin Degludec | 31 | $30,016 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 40 | $25,841 |
| SynjardyEmpagliflozin/Metformin Hcl | 27 | $25,295 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $3,135 | $493,295396 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $838 | $334,843264 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Synjardy | $423 | $297,484297 claims |
| AstraZenecaFarxiga | $23,890 | $118,980125 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $727 | $58,73681 claims |
| MerckJanuvia | $204 | $47,95740 claims |
| AbbVieSynthroid | $567 | $19,670231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 58 endocrinology providers in California.
Other endocrinology in Burbank
- Minh MachBurbank$559K
- Joseph HawkinsFresno$477K
- Michael BushBeverly Hills$380K
- Ashiq PatelLancaster$32K
- Paul AzerBeverly Hills$25K
- Michael TranAnaheim$16K
- Samuel MayedaOrange$11K
- Daniel KaplanSan Leandro$8K
- Amy van BuiMission Viejo$8K
- Sandeep ChaudharyLaguna Hills$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.